durvalumab,oleclumab
astrazeneca
['tnbc', 'platinum', 'oleclumab', 'durva', 'improve ']
the phase 2 study showed that adding the cd73 inhibitor oleclumab to durvalumab plus platinum-doublet chemotherapy does not improve the clinical benefit rate among women with treatment-na ve advanced tnbc. #drugdevelopment #oncology #esmo2022 
Early Drug Development Group is a CRO specialized in the preclinical and early clinical development of novel leads in oncology.